Effectiveness of Coenzyme Q10 on echocardiographic parameters of patients with Duchenne muscular dystrophy
Keywords:
Duchene muscular dystrophy, Coenzyme Q10, EchocardiographyAbstract
Background: Myocardial damage is a common complication in patients with Duchenne muscular dystrophy (DMD) that occurs due to myocardial replacement by fat and fibrosis. In recent years, efforts have been made toward finding new pharmacological agents with fewer complications which can be used as prophylactic before the symptoms. Coenzyme Q10 plays a central role in production of bioenergy in heart muscle and antioxidant in reperfusion condition of myocardial damaged muscle and leads to membrane stability and prevents cell death.
Objective: This study aimed at comparing the Effectiveness of coenzyme Q10 on echocardiographic parameters of pediatric patients with Duchenne muscular dystrophy.
Methods: This randomized clinical trial study (RCT) was carried out on 25 pediatric patients with pre-diagnosed DMD who attended the Children’s Medical Center (CMC), Tehran, Iran from February 2013 to 2015. The patients were randomly divided into two groups. Group-1; (n=12) was treated with coenzyme Q10 for six months and group-2 ;(n=13) received placebo for the same time. The primary aim was to compare the myocardial performance index (MPI), between the two groups at the end of six months. Data were analyzed by SPSS software (ver-16) and using T-Test.
Results: Twenty-five patients under study were divided into two groups of (Q10=12) and (placebo=13). Mean ages were 8.9±1.7 and 8.6±1.4 in Q10 and placebo groups (P=0.66). No significant difference was detected in MPI at all three views of mitral and tricuspid and septum respectively in two groups after the end of treatment (0.41±0.13, and 0.43±0.6; P=0.59), (0.45±0.12, and 0.46±0.1; P=0.05), and (0.45±0.06, and 0.45±0.1; P=0.31).
Conclusion: According to the results obtained from this study, coenzyme Q10 had no significant effect on improving the performance of echocardiographic parameters in patients with DMD.
Trial registration: The trial is registered at the Iranian Clinical Trial Registry (IRCT.ir) with the IRCT identification number IRCT2015070223018N1.
Funding: This research has been financially supported by the Research Council of Tehran University of Medical Sciences.
References
McNally EM. Duchenne muscular dystrophy: how bad is the heart? Heart. 2008; 94(8): 976-7. doi:
1136/hrt.2007.138461. PMID: 18625791.
Ciafaloni E, Moxley RT. Treatment options for Duchenne muscular dystrophy. Curr Treat Options Neurol.
; 10(2): 86-93. doi: 10.1007/s11940-008-0010-4. PMID: 18334131.
Ogata H, Nakatani S, Ishikawa Y, Negishi A, Kobayashi M, Ishikawa Y, et al. Myocardial strain changes
in Duchenne muscular dystrophy without overt cardiomyopathy. Int J Cardiol. 2007; 115(2): 190-5. doi:
1016/j.ijcard.2006.02.013. PMID: 16843547.
Pereira AM, Delgado V, Romijn JA, Smit JW, Bax JJ, Feelders RA. Cardiac dysfunction is reversed upon
successful treatment of Cushing's syndrome. Eur J Endocrinol. 2010; 162(2): 331-40. doi: 10.1530/EJE-09- 0621. PMID: 19933822.
Finsterer J. Cardiopulmonary support in Duchenne muscular dystrophy. Lung. 2006; 184(4): 205-15. doi:
1007/s00408-005-2584-x. PMID: 17006747.
Bhagavan HN, Chopra RK. Potential role of ubiquinone (coenzyme Q10) in pediatric cardiomyopathy. Clin
Nutr. 2005; 24(3): 331-8. doi: 10.1016/j.clnu.2004.12.005. PMID: 15896419.
Yiu EM, Kornberg AJ. Duchenne muscular dystrophy. J Paediatr Child Health. 2015; 51(8): 759-64. doi:
1111/jpc.12868. PMID: 25752877.
Shabanian R, Aboozari M, Kiani A, Seifirad S, Zamani G, Nahalimoghaddam A, et al. Myocardial
performance index and atrial ejection force in patients with Duchenne's muscular dystrophy.
Echocardiography. 2011; 28(10): 1088-94. doi: 10.1111/j.1540-8175.2011.01515.x. PMID: 21967284.
Buyse GM, Voit T, Schara U, Straathof CSM, D'Angelo MG, Bernert G, et al. Efficacy of idebenone on
respiratory function in patients with Duchenne muscular dystrophy not using glucocorticoids (DELOS): a
double-blind randomised placebo-controlled phase 3 trial. Lancet. 2015; 385(9979): 1748-57. doi:
1016/S0140-6736(15)60025-3. PMID: 25907158.
Mertens L, Ganame J, Claus P, Goemans N, Thijs D, Eyskens B, et al. Early regional myocardial
dysfunction in young patients with Duchenne muscular dystrophy. J Am Soc Echocardiogr. 2008; 21(9):
-54. doi: 10.1016/j.echo.2008.03.001. PMID: 18406573.
Markham LW, Kinnett K, Wong BL, Benson DW, Cripe LH. Corticosteroid treatment retards development
of ventricular dysfunction in Duchenne muscular dystrophy. Neuromuscul Disord. 2008; 18(5): 365-70. doi: 10.1016/j.nmd.2008.03.002. PMID: 18436445.
Buyse GM, Van der Mieren G, Erb M, D’hooge J, Herijgers P, Verbeken E, et al. Long-term blinded
placebo-controlled study of SNT-MC17/idebenone in the dystrophin deficient mdx mouse: cardiac
protection and improved exercise performance. Eur Heart J. 2009; 30(1): 116-24. doi:
1093/eurheartj/ehn406. PMID: 18784063, PMCID: PMC2639086.
Folkers K, Vadhanavikit S, Mortensen SA. Biochemical rationale and myocardial tissue data on the
effective therapy of cardiomyopathy with coenzyme Q10. Proc Natl Acad Sci U S A. 1985; 82(3): 901-4.
doi: 10.1073/pnas.82.3.901. PMID: 3856239, PMCID: PMC397155.
Singh RB, Neki NS, Kartikey K, Pella D, Kumar A, Niaz MA, et al. Effect of coenzyme Q10 on risk of
atherosclerosis in patients with recent myocardial infarction. Mol Cell Biochem. 2003; 246(1-2): 75-82.
doi: 10.1023/A: 1023408031111. PMID: 12841346.
Crane FL. Biochemical functions of coenzyme Q10. J Am Coll Nutr. 2001; 20(6): 591-8. doi:
1080/07315724.2001.10719063. PMID: 11771674
Langsjoen PH. Lack of effect of coenzyme Q on left ventricular function in patients with congestive heart
failure. J Am Coll Cardiol. 2000; 35(3): 816-7. doi: 10.1016/S0735-1097(99)00617-8. PMID: 10716489.
Efficacy and Tolerability of Idebenone in Boys With Cardiac Dysfunction Associated With Duchenne
Muscular Dystrophy (DELPHI). 2010. Available from:
http://www.clinicaltrials.gov/ct2/show/NCT00654784.
Blanche C, Fumeaux T, Polikar R. Heart failure with normal ejection fraction (HFNEF): is it worth
considering. Swiss Med Wkly. 2010; 140(5-6): 66-72. PMID: 20033859.
Rohde LE, Baldi A, Weber C, Geib G, Mazzotti NG, Fiorentini M, et al. Tei index in adult patients
submitted to adriamycin chemotherapy: failure to predict early systolic dysfunction. Int J Cardiovasc
Imaging. 2007; 23(2): 185-91. doi: 10.1007/s10554-006-9145-0. PMID: 16972144.
Buyse GM, Goemans N, Van den Hauwe M, Thijs D, de Groot IJ, Schara U, et al. Idebenone as a novel,
therapeutic approach for Duchenne muscular dystrophy: results from a 12 month, double-blind, randomized
placebo-controlled trial. Neuromuscul Disord. 2011; 21(6): 396-405. doi: 10.1016/j.nmd.2011.02.016.
PMID: 21435876.
Published
Issue
Section
License
Copyright (c) 2020 KNOWLEDGE KINGDOM PUBLISHING
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
